PROVECTUS BIOPHARMACEUTICALS, INC.

For the period ended Mar 31, 2026. Filed May 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 14, 2026

PVCT$0.04-17.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Deficit

FOR THE THREE MONTHS ENDED MARCH 31, 2026

(Unaudited)

Preferred Stock Series D · Preferred Stock Series D-1 · Common Stock · Additional Paid-In · Accumulated Other Comprehensive · Accumulated · Non- controlling
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Loss	Deficit	Interest	Total
Balance at January 1, 2026	956,985	$957	14,183,315	$14,183	420,279,879	$420,280	$256,179,846	$(60,191)	$(262,853,812)	$(3,981)	$(6,302,718)
Issuance of common stock of majority-owned subsidiary	-	-	-	-	-	-	66,767	-	-	8,233	75,000
Conversion of 2025 Notes to Series D-1 Preferred Stock	-	-	171,735	172	-	-	491,329	-	-	-	491,501
Stock-based compensation:
Amortization of stock options	-	-	-	-	-	-	306,051	-	-	-	306,051
Comprehensive loss:
Net loss	-	-	-	-	-	-	-	-	(1,290,454)	(10,495)	(1,300,949)
Other comprehensive income	-	-	-	-	-	-	-	285	-	-	285
Balance at March 31, 2026	956,985	$957	14,355,050	$14,355	420,279,879	$420,280	$257,043,993	$(59,906)	$(264,144,266)	$(6,243)	$(6,730,830)

PROVECTUS BIOPHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE THREE MONTHS ENDED MARCH 31, 2025

(Unaudited)

Preferred Stock Series D · Preferred Stock Series D-1 · Common Stock · Additional Paid-In · Accumulated Other Comprehensive · Accumulated · Non- controlling
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Loss	Deficit	Interest	Total
Balance at January 1, 2025	956,985	$957	13,106,223	$13,106	420,279,879	$420,280	$251,090,027	$(60,741)	$(257,422,961)	$(9,893)	$(5,969,225)
Issuance of common stock of majority-owned subsidiary	-	-	-	-	-	-	634,782	-	-	65,218	700,000
Conversion of 2022 Notes to Series D-1 Preferred Stock	-	-	365,400	365	-	-	1,046,329	-	-	-	1,046,694
Stock-based compensation:
Amortization of stock options	-	-	-	-	-	-	315,100	-	-	-	315,100
Comprehensive loss:
Net loss	-	-	-	-	-	-	-	-	(1,140,108)	(21,494)	(1,161,602)
Other comprehensive income	-	-	-	-	-	-	-	52	-	-	52
Balance at March 31, 2025	956,985	$957	13,471,623	$13,471	420,279,879	$420,280	$253,086,238	$(60,689)	$(258,563,069)	$33,831	$(5,068,981)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.